Cargando…
COVID‐19 and the Emerging Regulatory Guidance for Ongoing Clinical Trials in the European Union
The coronavirus disease 2019 (COVID‐19) pandemic and the accompanying control measures have significantly affected clinical trial (CT) conduct, and sponsors have needed to make rapid changes to their CT operations. As a result, regulatory guidance was pivotal during the initial phases of the pandemi...
Autores principales: | de Jong, Amos Jochanan, Santa‐Ana‐Tellez, Yared, van Thiel, Ghislaine José Madeleine Wilhelmien, Zuidgeest, Mira Gerta Petra, Siiskonen, Satu Johanna, Mistry, Dinesh, de Boer, Anthonius, Gardarsdottir, Helga |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8013428/ https://www.ncbi.nlm.nih.gov/pubmed/33666223 http://dx.doi.org/10.1002/cpt.2225 |
Ejemplares similares
-
Which decentralised trial activities are reported in clinical trial protocols of drug trials initiated in 2019–2020? A cross-sectional study in ClinicalTrials.gov
por: de Jong, Amos J, et al.
Publicado: (2022) -
Opportunities and Challenges for Decentralized Clinical Trials: European Regulators’ Perspective
por: de Jong, Amos J., et al.
Publicado: (2022) -
A cross-sectional survey on the early impact of COVID-19 on the uptake of decentralised trial methods in the conduct of clinical trials
por: Suman, Arnela, et al.
Publicado: (2022) -
Enabling appropriate use of antibiotics: review of European Union procedures of harmonising product information, 2007 to 2020
por: Opalska, Aleksandra, et al.
Publicado: (2020) -
Quality of reporting of drug exposure in pharmacoepidemiological studies
por: Hempenius, Mirjam, et al.
Publicado: (2020)